drugset
drugset / Trial / NCT05038618

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

NCT05038618 ↗

Phase 2 Completed 399 enrolled Medigen Vaccine Biologics Corp.
NaSingle-groupOpen-labelPrevention

Summary

This sub-study is a prospective open-label, single-center study to demonstrate comparability of different manufacturing scales.

Timeline

Start
2021-08-02
Primary completion
2021-10-14
Completion
2022-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MVC-COV1901 Vaccine — Intramuscular

Indications

No indication recorded.